Diabetes Mellitus Interagency Coordinating Committee (DMICC) : NIDDK


Diabetes Mellitus Interagency Coordinating Committee (DMICC)

Coordinating the Federal Investment in Diabetes Research to
Improve the Health of Americans

Originally authorized by Public Law 93-354 and established in 1974, the Diabetes Mellitus Interagency Coordinating Committee (DMICC) is chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and includes other members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities (see “Who Are the DMICC Members?”). The DMICC facilitates cooperation, communication, and collaboration on diabetes among these government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other’s expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate.

Who Are the DMICC Members?

The DMICC currently includes representatives from:

Member agencies represent a spectrum of diabetes activities across the government, contributing at various stages to fostering research and to a paradigm of translating the results of diabetes biomedical and behavioral research from the bench to the bedside to the community.

How Does the DMICC Coordinate Diabetes Activities Across the Government?

Through Meetings: DMICC meetings provide in-depth information from the various programs and from experts outside the government on diabetes and its complications; help to catalyze new projects; and guide the progress of projects involving several agencies.

Through Strategic Planning: The DMICC has taken a leadership role with respect to strategic planning for diabetes research. For example, Advances and Emerging Opportunities in Type 1 Diabetes Research: A Strategic Plan (August 2006) was developed under the auspices of the DMICC with broad external input, and the DMICC is monitoring its implementation. (See: www.T1Diabetes.nih.gov/plan) The DMICC also recently held a meeting with external scientific experts to obtain input on future opportunities for new clinical trials for type 1 and type 2 diabetes. Many ongoing clinical studies are collaborative efforts involving multiple NIH Institutes and Centers and other government components, and DMICC leadership was important for research planning efforts.

Through Development and Oversight of Special Programs: To meet the need for nationwide efforts to promote adoption of proven methods to treat diabetes, the DMICC established the National Diabetes Education Program (NDEP). Jointly led by NIH and CDC, the NDEP recently published a 10 year report on its accomplishments. The DMICC plays an important role in coordinating and guiding diabetes research by overseeing the trans-HHS Special Statutory Funding Program for Type 1 Diabetes Research. This special program is spearheaded by the NIDDK and involves numerous Institutes and Centers of the NIH, as well as the CDC. The DMICC recently published an evaluation of the program’s first 10 years demonstrating its success in advancing diabetes research.

Through Evaluation of Ongoing Diabetes Efforts: The DMICC has spearheaded efforts to assess the status of federally-supported research efforts on diabetes and its complications. For example, in April 2008, the DMICC convened a group of external scientific experts to perform a mid-course assessment of ongoing clinical research efforts supported by the trans-HHS Special Statutory Funding Program for Type 1 Diabetes Research.

What Diabetes Activities Have Been Successfully Coordinated Across the Government?

Examples Include:

  • Promoting diabetes prevention and control through creation and support of the National Diabetes Education Program (NDEP), the leading federal government education program of this kind.
  • Preventing or delaying type 2 diabetes through the Diabetes Prevention Program (DPP), and translating and disseminating the positive results of this clinical trial as public health messages via diabetes prevention awareness campaigns targeting high risk populations.
  • Addressing diabetes in communities at risk around the U.S., through programs such as Diabetes Education in Tribal School and the statutory Special Diabetes Program for Indians, and through educational campaigns addressing populations disproportionately affected by diabetes.
  • Ensuring consistent information about diabetes for the public through a process in which components of DHHS, voluntaries, professional organizations, and others agree to use the same statistics and diagnostic criteria for diabetes and pre-diabetes in the U.S.
  • Partnering on research and regulatory issues for the “artificial pancreas” and for development of a guidance for diabetes therapeutics development through an interagency working group, public workshops, and other efforts.
  • Partnering on surveillance efforts for diabetes prevalence, incidence, and control, as well as on studies to identify effective practices and barriers to improved care in managed care and other health care delivery settings.
  • Collaborating on the design of studies on islet transplantation as a novel therapy for type 1 diabetes.
  • Developing research initiatives and activities to address specific problems such as foot ulcers, the emergence of type 2 diabetes in children, and metabolic complications of atypical psychotropic drugs following DMICC meetings targeting these specific issues.

What Are the Next Steps for the DMICC?

The DMICC continues to improve the dissemination of information about diabetes and enhance coordination of federal efforts to advance diabetes research and improve the health of Americans with or at risk for diabetes. Future meetings will focus on new opportunities for collaboration, forging new partnerships, and strategic planning to ensure effective deployment of federal resources to better understand, prevent, and treat diabetes in the U.S.

This Website is under construction (Last update: November 7, 2008). Please return for new content coming soon.

Page last updated: November 07, 2008

General inquiries may be addressed to: Office of Communications & Public Liaison
Building 31. Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560
For information about NIDDK programs: 301.496.3583

The National Institutes of Health   Department of Health and Human Services   USA.gov is the U.S. government's official web portal to all federal, state, and local government web resources and services.  HONcode Seal - Link to the Health on the Net Foundation